Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients

Chinese Medical Journal

Volumn 125, Issue 4, 2012, Pages 583-587

  Sun, Cong Cong ^a   Luo, Fei Fei ^a   Wei, Lei ^a   Lei, Mi ^a   Li, Guo Fei ^b   Liu, Zhuo Lin ^a   Le, Wei Dong ^c,d   Xu, Ping Yi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b HENAN UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Disease progression; Parkinson's disease; Uric acid

Indexed keywords

CREATININE; URIC ACID;

ADULT; ARTICLE; BLOOD ANALYSIS; CHINESE; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE; RISK ASSESSMENT; STUDENT T TEST; URINARY EXCRETION;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; URIC ACID;

EID: 84863161476     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.04.005     Document Type: Article

References (23)

1. Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin Med J 2001; 114: 227-234.
2. Ren JP, Zhao YW, Sun XJ. Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice. Chin Med J 2009; 122: 2366-2371.
3. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 1986; 235: 747-754.
4. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80: 101-110.
5. Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011; 43: 246-250.
6. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994; 33: 419-425.
7. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996; 144: 480-484.
8. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460-1468.
9. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008; 167: 831-838.
10. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005; 58: 797-800.
11. Schiess M, Oh I. Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch Neurol 2008; 65: 698-699.
12. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008; 65: 716-723.
13. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009; 111: 724-728.
14. Winquist A, Steenland K, Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 2010; 25: 932-936.
15. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
17. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis risk in Communities (ARIC) study. Am J Epidemiol 2009; 169: 1064-1069.
18. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 2007; 22: 1133-1137.
19. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78: 6858-6862.
20. Whiteman M, Ketsawatsakul U, Halliwell B. A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci 2002; 962: 242-259.
21. Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol 2010; 281: 229-266.
22. Bierer DW, Quebbemann AJ. Effect of l-Dopa on renalhandling of uric acid. J Pharmacol Exp Ther 1982; 223: 55-59.
23. Pinheiro-Carrera M, Tomaz C, Huston JP, Dai H, Carey RJ. l-Dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation. Life Sci 1994; 55: 991-997.